Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT07510100 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07510100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07510100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 10, 2026
Completion date
January 31, 2030
Enrollment
17 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma